Central Nervous System Activity of Lazertinib in EGFR ‐Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‐LU20‐15 and LU21‐01
Dong Hyun Kim, Min Hee Hong, Hyun Ae Jung, Tae Min Kim et autres
0 citationsThoracic Cancer
Myung‐Ju Ahn
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
1307Publications signalées
75142Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
Lung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentColorectal Cancer Treatments and Studies
Publications récentes
A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors
Lillian L. Siu, Omid Hamid, Reva Schneider, Jordi Rodón et autres
0 citationsClinical Cancer Research
T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop
May‐Lucie Meyer, Solange Peters, Myung‐Ju Ahn, Isabelle Beuchat et autres
0 citationsCancer Treatment Reviews
Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S2 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Methods S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Table S5 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Table S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S1 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
Supplementary Figure S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.